Sign in to view content

Assessment of the Inclusion of Racial/Ethnic Minorities in Retina Clinical Trials

Vivienne S. Hau, MD, PhD

Video
Published 2022

Related

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021
1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025
Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2024

Category: Dry AMD

See more